Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting.

[1]  Thomas D. Giles,et al.  Consensus recommendations for the management of chronic heart failure: Introduction , 1999 .

[2]  J. Cohn,et al.  Consensus recommendations for the management of chronic heart failure. On behalf of the membership of the advisory council to improve outcomes nationwide in heart failure. , 1999, The American journal of cardiology.

[3]  C. Kumana,et al.  Natriuretic peptides--relevance in cardiovascular disease. , 1998, JAMA.

[4]  Bernard C. K. Choi,et al.  Slopes of a receiver operating characteristic curve and likelihood ratios for a diagnostic test. , 1998, American journal of epidemiology.

[5]  M. Kinoshita,et al.  Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. , 1998, American heart journal.

[6]  M. Redfield,et al.  Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. , 1998, American journal of physiology. Heart and circulatory physiology.

[7]  M. Emdin,et al.  Circulating levels of cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure , 1998, Journal of endocrinological investigation.

[8]  K. Dickstein.  Natriuretic peptides in detection of heart failure , 1998, The Lancet.

[9]  H. Tunstall-Pedoe,et al.  Biochemical detection of left-ventricular systolic dysfunction , 1998, The Lancet.

[10]  J. McMurray,et al.  Brain natriuretic peptide is stable in whole blood and can be measured using a simple rapid assay: implications for clinical practice , 1997, Heart.

[11]  P. Poole‐Wilson,et al.  Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care , 1997, The Lancet.

[12]  D. Fukai,et al.  Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. , 1997, Circulation.

[13]  J. McMurray,et al.  Value of the electrocardiogram in identifying heart failure due to left ventricular systolic dysfunction , 1996, BMJ.

[14]  K. Nakao,et al.  Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an "emergency" cardiac hormone against ventricular overload. , 1995, The Journal of clinical investigation.

[15]  A. Struthers.  Prospects for using a blood sample in the diagnosis of heart failure. , 1995, QJM : monthly journal of the Association of Physicians.

[16]  A. Richards,et al.  Plasma brain natriuretic peptide in assessment of acute dyspnoea , 1994, The Lancet.

[17]  R. Wuerz,et al.  Effects of prehospital medications on mortality and length of stay in congestive heart failure. , 1992, Annals of emergency medicine.

[18]  L. Stevenson,et al.  The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. , 1989, JAMA.

[19]  N. Minamino,et al.  Cloning and sequence analysis of cDNA encoding a precursor for porcine brain natriuretic peptide , 1988 .

[20]  R. Devereux,et al.  Recommendations Concerning Use of Echocardiography in Hypertension and General Population Research , 1987, Hypertension.

[21]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.